Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;33(12):2660-4.
doi: 10.2337/dc10-0613.

Impaired fasting glucose in cystic fibrosis

Brigitte I Frohnert  1 , Katie Larson Ode, Antoinette Moran, Brandon M Nathan, Theresa Laguna, Bonnie Holme, William Thomas
Affiliations

Impaired fasting glucose in cystic fibrosis

Brigitte I Frohnert et al. Diabetes Care. 2010 Dec.

Abstract

Objective: While glucose tolerance abnormalities are common in cystic fibrosis (CF), impaired fasting glucose (IFG) has scarcely been explored. No studies have examined the relation between IFG and clinical status.

Research design and methods: Data were retrieved from the University of Minnesota CF database on oral glucose tolerance tests (OGTTs) performed in 1996-2005. Subjects were identified as normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or CF-related diabetes without fasting hyperglycemia (CFRD FH-). Patients with fasting hyperglycemia were excluded. The presence of IFG was assessed within each category. In a separate case-control cohort study, subjects with IFG were matched to CF control subjects by age, sex, and OGTT class to explore outcomes.

Results: For the total population (n = 310), the prevalence of IFG was 22%, and by OGTT class was NGT 14%, IGT 31%, CFRD FH- 53%. Within the cohort study, mortality was significantly reduced in IFG (two vs. nine deaths, odds ratio [OR] = 0.2 [95% CI 0.04-0.9]). IFG did not confer increased risk of progression to diabetes (OR 0.66 [0.29-1.48]). Lung function was better in pediatric IFG subjects with IGT and not significantly worse in adults with IGT or adults and children with NGT and CFRD FH-. BMI was not significantly different in IFG subjects versus control subjects.

Conclusions: Contrary to expectations in patients with CF, IFG appeared to be associated with improved survival and was not associated with worse nutritional or pulmonary status or increased progression to fasting hyperglycemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Model for fasting blood glucose and IFG in CF. A: In the normal population, fasting HGP is balanced by total body glucose utilization (GU). B: Inflammation, undernutrition, and perhaps the CF gene defect increase GU in CF patients. HGP is elevated for reasons that are not understood very well, but fasting glucose levels are normal when HGP and GU are in balance. C: In healthier CF patients, HGP is similarly elevated but GU is reduced, leading to IFG.
See this image and copyright information in PMC

References

    1. Benjamin SM, Cadwell BL, Geiss LS, Engelgau MM, Vinicor F: A change in definition results in an increased number of adults with prediabetes in the United States. Arch Intern Med 2004;164:2386. - PubMed
    1. Duncan GE: Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999–2002. Arch Pediatr Adolesc Med 2006;160:523–528 - PubMed
    1. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, Tullis E, Liou TG, Allen H: Cystic Fibrosis Related Diabetes Therapy Study Group. Insulin therapy to improve BMI in cystic fibrosis–related diabetes without fasting hyperglycemia: results of the Cystic Fibrosis Related Diabetes Therapy Trial. Diabetes Care 2009;32:1783–1788 - PMC - PubMed
    1. Mueller-Brandes C, Holl RW, Nastoll M, Ballmann M: New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. Eur Respir J 2005;25:715–717 - PubMed
    1. Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA: Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. J Pediatr 2007;151:653–658 - PubMed

Publication types